Presentation is loading. Please wait.

Presentation is loading. Please wait.

Real-life treatment of cholinergic urticaria with omalizumab

Published byせい うなだ Modified over 5 years ago

Similar presentations

Presentation on theme: "Real-life treatment of cholinergic urticaria with omalizumab"— Presentation transcript:

1 Real-life treatment of cholinergic urticaria with omalizumab
Sabine Altrichter, MD, Mati Chuamanochan, MD, Henriette Knoth, Aida Asady, MD, Tatevik Ohanyan, MD, Martin Metz, MD, Marcus Maurer, MD  Journal of Allergy and Clinical Immunology  Volume 143, Issue 2, Pages e8 (February 2019) DOI: /j.jaci Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

2 Fig 1 A, Response rate to the final dose of omalizumab in patients with CholU (n = 16). B, Timeline and the clinical response of 6 patients who received omalizumab updosing. The dosing and intervals (in weeks) of individual treatment are shown in the squares. *Patient achieved complete response initially and became a major responder later. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

3 Fig E1 Response rate to the standard dose of omalizumab (300 mg every 4 weeks) in patients with CholU (n = 15). Response groups are depicted in different colors. Numbers give the percentage of patients in the various response groups. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

4 Fig E2 Display of response rates to the final omalizumab dose, separated by sex. Response groups are depicted in different colors. CR, Complete response; MR, major response; NR, no response; PR, partial response. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

5 Fig E3 A-D, Correlation of the clinical response to the final omalizumab dose and patient age (Fig E3, A), age at onset (Fig E3, B), duration of disease (Fig E3, C), and total IgE level (Fig E3, D). None of the response groups were significantly different in any figure. CR, Complete response; MR, major response; NR, no response; PR, partial response. Journal of Allergy and Clinical Immunology  , e8DOI: ( /j.jaci ) Copyright © 2018 American Academy of Allergy, Asthma & Immunology Terms and Conditions

Download ppt "Real-life treatment of cholinergic urticaria with omalizumab"

Similar presentations

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,

Joint modeling of parentally reported and physician-confirmed wheeze identifies children with persistent troublesome wheezing Danielle C.M. Belgrave, MSc,
Severe adult-onset asthma: A distinct phenotype

Severe adult-onset asthma: A distinct phenotype
D-dimer: A biomarker for antihistamine-resistant chronic urticaria

D-dimer: A biomarker for antihistamine-resistant chronic urticaria
Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 

Jonathan A. Bernstein, MD, David M. Lang, MD, David A. Khan, MD 
The natural history of soy allergy

The natural history of soy allergy
Allergen immunotherapy: A practice parameter third update

Allergen immunotherapy: A practice parameter third update
Risk of an asthma exacerbation after bariatric surgery in adults

Risk of an asthma exacerbation after bariatric surgery in adults
Pharmacologic rationale for treating allergic and nonallergic rhinitis

Pharmacologic rationale for treating allergic and nonallergic rhinitis
Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,

Responsiveness and minimal important difference of the urticaria control test  Tatevik Ohanyan, MD, Nicole Schoepke, MD, Bediha Bolukbasi, MD, Martin Metz,
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,

The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria  Marcus Maurer, MD, Allen Kaplan, MD, Karin Rosén, MD, PhD, Michael Holden,
Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 

Santa Jeremy Ono, BA, PhD, Mark B. Abelson, MD 
Ann-Marie M. Schoos, MD, PhD, Jacob D

Ann-Marie M. Schoos, MD, PhD, Jacob D
Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,

Increased IgE levels are linked to faster relapse in patients with omalizumab- discontinued chronic spontaneous urticaria  Ragip Ertas, MD, Kemal Ozyurt,
Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,

Efficacy and safety of canakinumab in Schnitzler syndrome: A multicenter randomized placebo-controlled study  Karoline Krause, MD, Athanasios Tsianakas,
Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,

Complete remission in 3 of 3 anti-IL-6–treated patients with Schnitzler syndrome  Karoline Krause, MD, Eugen Feist, MD, Michael Fiene, MD, Tilmann Kallinich,
David A. Khan, MD  Journal of Allergy and Clinical Immunology 

David A. Khan, MD  Journal of Allergy and Clinical Immunology 
Shyam Joshi, MD, David A. Khan, MD 

Shyam Joshi, MD, David A. Khan, MD 
Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 

Dorothy M. Ryan, MD, Stephen J. Fowler, MD, Robert M. Niven, MD 
Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study

Incident asthma and Mycoplasma pneumoniae: A nationwide cohort study
Is 9 more than 2 also in allergic airway inflammation?

Is 9 more than 2 also in allergic airway inflammation?

Similar presentations

Ads by Google